home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.77 +1.33 (+2.54%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

34 35 Next >

Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? ↗

December 11, 2023

A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.

Via The Motley Fool

The 3 Best Cathie Wood Stocks to Buy in December ↗

December 10, 2023

Cathie Wood stocks had a great November and are well-positioned to keep performing well, given the favorable macro backdrop.

Via InvestorPlace

Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy? ↗

December 10, 2023

The big biotech's shares have been on the rise this year.

Via The Motley Fool

FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗

December 08, 2023

The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y

Via Benzinga

Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review ↗

December 08, 2023

Treasury yields and crude oil came off multimonth lows on Friday's jobs report.

Via Investor's Business Daily

Topics Artificial Intelligence

Is This News a Setback or a Step Forward for CRISPR Therapeutics? ↗

December 06, 2023

It's important to look at the news through a long-term lens.

Via The Motley Fool

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

December 08, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried? ↗

December 08, 2023

The timing of the cuts is setting off alarm bells, but the situation is under control.

Via The Motley Fool

Healthcare Gems: 3 Essential Long-Term Stock Picks ↗

December 07, 2023

Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks.

Via InvestorPlace

This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics ↗

December 07, 2023

Shareholders will do well to prepare themselves for how regulators might react.

Via The Motley Fool

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

December 06, 2023

Via Benzinga

The Latest Analyst Ratings for CRISPR Therapeutics ↗

December 05, 2023

Via Benzinga

5 Unstoppable Trends to Invest $1,000 in for 2024 ↗

December 07, 2023

These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.

Via The Motley Fool

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy ↗

December 07, 2023

These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.

Via InvestorPlace

CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases ↗

December 05, 2023

Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T

Via Benzinga

Better Growth Stock: CRISPR Therapeutics vs. Invitae ↗

December 05, 2023

One of these stocks may be riskier than the other...

Via The Motley Fool

The Market's Up This Year. Do You Feel Like You Are Winning? ↗

December 04, 2023

We've also got a look at two stocks worth watching and the popular toys for this holiday season.

Via The Motley Fool

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗

December 04, 2023

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

Via The Motley Fool

Where Will Vertex Pharmaceuticals Be in 10 Years? ↗

December 04, 2023

Vertex shares have soared 400% over the past decade.

Via The Motley Fool

If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today ↗

December 04, 2023

CRISPR Therapeutics' shares advanced in the double-digits this year.

Via The Motley Fool

Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now ↗

December 03, 2023

The one thing these two stocks have in common is tremendous growth prospects.

Via The Motley Fool

An Important History Lesson for Gene-Editing Investors ↗

December 02, 2023

Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.

Via The Motley Fool

5 Top Stocks to Buy Before 2024 ↗

December 02, 2023

These stocks have room to run -- next year and over the long term.

Via The Motley Fool

Five Best Performing Stocks Of The Top ETF Of November ↗

December 01, 2023

Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way.

Via Talk Markets

Topics ETFs

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

December 01, 2023

It's not as long a shot as some might think.

Via The Motley Fool

Looking for Growth? 2 Top Stocks to Buy Hand Over Fist ↗

December 01, 2023

These stocks offer enormous long-term growth potential.

Via The Motley Fool

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception ↗

November 29, 2023

The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.

Via Benzinga

Topics ETFs

Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback' ↗

November 29, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here.

Via Benzinga

3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗

November 28, 2023

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

Via InvestorPlace

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com